Citius Pharmaceuticals (NASDAQ:CTXR) Shares Gap Down – What’s Next?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $4.15, but opened at $3.60. Citius Pharmaceuticals shares last traded at $3.61, with a volume of 360,299 shares.

Wall Street Analysts Forecast Growth

CTXR has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th. D. Boral Capital reissued a “hold” rating on shares of Citius Pharmaceuticals in a report on Friday, November 22nd.

Citius Pharmaceuticals Stock Down 13.3 %

The business has a 50 day moving average price of $9.15 and a 200 day moving average price of $14.13.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in CTXR. Armistice Capital LLC acquired a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at $5,928,000. Geode Capital Management LLC increased its holdings in Citius Pharmaceuticals by 14.1% in the third quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock valued at $941,000 after buying an additional 232,656 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Citius Pharmaceuticals in the second quarter worth about $118,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Citius Pharmaceuticals during the 2nd quarter worth about $69,000. Finally, Vanguard Group Inc. boosted its stake in shares of Citius Pharmaceuticals by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after acquiring an additional 104,889 shares in the last quarter. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.